Sign in

    Thomas Bowers

    Research Analyst at Danske Bank

    Thomas Bowers was previously a Senior Equity Analyst at Danske Bank, focusing on fundamental research and stock recommendations primarily across general and diversified sectors. He covered companies such as AKBLF, delivering a 40% success rate on his stock recommendations with an average return per transaction of 16.8%, including a notably profitable rating generating a 113.9% return over a twelve-month period. Bowers spent 18 years at Danske Bank, departing in December 2024 to join SEB, and is recognized for his longstanding expertise and impact in Nordic equity research. Professional credentials and licensing information are not publicly listed, but his career indicates extensive analyst experience and industry recognition.

    Thomas Bowers's questions to Zealand Pharma A/S/ADR (ZLDPF) leadership

    Thomas Bowers's questions to Zealand Pharma A/S/ADR (ZLDPF) leadership • Q3 2024

    Question

    Thomas Bowers asked if CRP reduction data was available from the petrelintide Phase I trial, questioned the strategy for the petrelintide/GLP-1 combination trial, and asked if the petrelintide weight loss curve was showing signs of plateauing.

    Answer

    CEO Adam Steensberg responded. He confirmed CRP data was not a part of the small Phase I study but is an expected effect. For the combination trial, the strategy is to add a small amount of GLP-1 on top of an effective dose of petrelintide for a more patient-friendly approach. Mr. Steensberg firmly disagreed that the weight loss curve was tailing off, attributing its shape to the low-BMI population and short study duration, and expressed no concerns about reaching long-term weight loss targets.

    Ask Fintool Equity Research AI

    Thomas Bowers's questions to Zealand Pharma A/S/ADR (ZLDPF) leadership • Q3 2024

    Question

    Thomas Bowers from Danske Bank asked if C-reactive protein (CRP) reduction data was available from the petrelintide Phase I study and if it could be expected from dapiglutide. He also inquired about the strategy for the petrelintide and GLP-1 combination trial and questioned whether the petrelintide efficacy curve showed signs of tailing off.

    Answer

    President and CEO Adam Steensberg stated that CRP data should not be expected from the small Phase I study but is anticipated in the future based on the drug class. He described the combination strategy as adding a small amount of a GLP-1 on top of an effective dose of petrelintide for a more patient-friendly approach. He firmly rejected the idea that the weight loss curve was tailing off, attributing its shape to the low baseline BMI of participants and the nature of a Phase I study without diet and exercise interventions.

    Ask Fintool Equity Research AI